Back grey_arrow_rt.gif
 
Archived NATAP Articles from August 2003
 
null.gif
 
 
  1. Beware of Drug Holidays before HIV Salvage Therapy - (8/29/03)

    2.  
  2. Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus - (8/29/03)

    3.  
  3. Changes in Metabolic Profile Among Antiretroviral-Naïve Patients Initiating Protease Inhibitor Versus Non-Protease Inhibitor Containing HAART Regimens - (8/27/03)

    4.  
  4. Use of HAART Among Young People Living with HIV - (8/26/03)

    5.  
  5. New Entry Inhibitor in Development - (8/25/03)

    6.  
  6. Decreased Bone Mineral Density Due to Time with HIV, not ART - (8/25/03)

    7.  
  7. HBV, HBV Vaccinations, and HAART - (8/25/03)

    8.  
  8. Treatments for lipoatrophy. Are there improvements? Are they noticeable? - (8/25/03)

    9.  
  9. HIV Topical Microbicide Early Trials Should Have Condom Only Third Arm, Cmte. Members Say - (8/25/03)

    10.  
  10. Clinics Offering Free or Low Cost Hepatitis A and Hepatitis B Vaccinations In New York State - (8/20/03)

    11.  
  11. Bone Effects of Tenofovir - (8/19/03)

    12.  
  12. The Impact of Hepatitis C Virus Coinfection on HIV Progression Before and After Highly Active Antiretroviral Therapy - (8/18/03)

    13.  
  13. Coadministration of Milk Thistle and Indinavir in Healthy Subjects - (8/18/03)

    14.  
  14. Microbicides: STD Protection With or Without Contraception - (8/18/03)

    15.  
  15. Background Information Microbicide Drug Candidates Including Cyanovirin-N To Prevent Anal & Vaginal HIV Transmission - (8/18/03)

    16.  
  16. Switch From NNRTI Regimen to Trizivir: viral load & choleserol changes - (8/18/03)

    17.  
  17. FDA Hearing on Microbicides to Prevent HIV Transmission to Women: trial considerations - (8/18/03)

    18.  
  18. GILEAD INITIATES STUDY 934, A 48-WEEK CLINICAL TRIAL EVALUATING VIREAD AND EMTRIVA VERSUS COMBIVIR - (8/14/03)

    19.  
  19. The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons - (8/14/03)

    20.  
  20. Brief Report: Effect of Antioxidants on Glucose Metabolism and Plasma Lipids in HIV-Infected Subjects With Lipoatrophy - (8/14/03)

    21.  
  21. Virological rebound after suppression on highly active antiretroviral therapy - (8/14/03)

    22.  
  22. Can interferon prolong life? - (8/14/03)

    23.  
  23. Maine: inmates with hepatitis sue for treatment - (8/13/03)

    24.  
  24. IAS - MaxCmin 2 study - Reported by Mike Youle, MD, Royal Free Hospital, London, UK - (8/11/03)

    25.  
  25. Antiviral efficacy of adefovir dipivoxil similar regardless of hepatitis B genotype - (8/11/03)

    26.  
  26. Prevalence of Unsafe Sexual Behavior Among HIV-Infected Individuals: The Swiss HIV Cohort Study - (8/11/03)

    27.  
  27. Stability of Adherence to Highly Active Antiretroviral Therapy Over Time Among Clients Enrolled in the Treatment Adherence Demonstration Project - (8/11/03)

    28.  
  28. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort - (8/11/03)

    29.  
  29. Dear Doctor Letter From Bristol Myers Squibb - (8/8/03)

    30.  
  30. News From 2003 CDC Prevention Conference: new guidelines for health care providers to incorporate HIV prevention into ongoing care of persons living with HIV - (8/8/03)

    31.  
  31. STIs and Effect on Lipids, HIV Drug Resistance, and Viral Load - (8/7/03)

    32.  
  32. Fosamprenavir: new version of amprenavir; GSK Drug Pipeline; herpes & HIV - (8/5/03)

    33.  
  33. AIDS Cases on the Rise in United States - (8/5/03)

    34.  
  34. Go-Ahead for Anti-AIDS Microbicide Gel Trials - (8/5/03)

    35.  
  35. SQV/r, ATV, ATV/r in Treatment-Experienced: boosted PI Therapy Antiretrovirals in subsequent regimens Written by Dr Graeme Moyle, London. Chelsea & Westminster Hospital - (8/4/03)

    36.  
  36. MaxCmin2 Study: Kaletra vs saquinavir/ritonavir; final 48-week results - (8/4/03)

    37.  
  37. HIV Viral Dynamics: viral fitness, genetic diversity, progresion, co-receptor use Written by Mike Youle, MD, Royal Free Hospital, London, UK - (8/4/03)

    38.  
  38. New Atazanavir Information - (8/4/03)

    39.  
  39. Pulmonary Hypertension: Finally a treatment trial! Reported by Judith Aberg, MD, Washington University, St Louis, Missouri, and the ACTG - (8/4/03)

    40.  
  40. Prisons to Reduce Hepatitis Treatment - (8/4/03)

    41.  
  41. Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population - (8/4/03)

    42.  
  42. Atazanavir (Reyataz): new PI - (8/4/03)

    43.  
  43. Press Release from Vertex Pharmaceuticals - (8/4/03)

    44.  
  44. Lipoatrophy and Mitochondrial Toxicity Issues at the 5th Lipodystrophy Conference - Cecilia Shikuma, MD, University of Hawaii and the ACTG (8/4/03)

    45.  
  45. In Maine, AIDS, HIV Cases on Rise - (8/4/03)

    46.  
  46. High Herpes Rate Found in Metro Atlanta - (8/4/03)

    47.  
  47. Glucose metabolism/insulin resistance, lipids and cardiovascular: report from Paris, IAS & Lipodystrophy Conferences - Michael Dube, MD, University of Indiana and the ACTG (7/10/03)

    48.